Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

The global epidemiology of nonalcoholic fatty liver disease... : Hepatology The global
epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. The
estimated global incidence of NAFLD is 47 cases per 1,000 population and is higher among …

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …

Background Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-
specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Integrins are considered the main cell-adhesion transmembrane receptors that play
multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …